# A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

> **NCT04718103** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 397 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** GSK3511294
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04718103
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-04
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718103, "A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04718103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*